A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic

- Lal, Anoushka P., Foong, Yi Chao, Roos, Izanne, Lechner-Scott, Jeannette, John, Nevin, Soysal, Aysun, D’Amico, Emanuele, Gouider, Riadh, Mrabet, Saloua, Gross-Paju, Katrin, Cárdenas‑Robledo, Simón, Moghadasi, Abdorreza Naser, Sanfilippo, Paul G., Sa, Maria Jose, Gray, Orla, Oh, Jiwon, Reddel, Stephen, Ramanathan, Sudarshini, Al-Harbi, Talal, Altintas, Ayse, Hardy, Todd A., Ozakbas, Serkan, Alroughani, Raed, Spelman, Tim, Kermode, Allan G., Surcinelli, Andrea, Laureys, Guy, Eichau, Sara, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Hodgkinson, Suzanne, Ramo-Tello, Cristina, Maimone, Davide, Rath, Louise, McCombe, Pamela, Spitaleri, Daniele, Sanchez-Menoyo, Jose Luis, Yetkin, Mehmet Fatih, Baghbanian, Seyed Mohammad, Karabudak, Rana, Al-Asmi, Abdullah, Jakob, Gregor Brecl, Khoury, Samia J., Etemadifar, Masoud, Levitz, David, van Pesch, Vincent, Buzzard, Katherine, Taylor, Bruce, Butzkueven, Helmut, Van der Walt, Anneke, Fabis-Pedrini, Marzena, Foschi, Matteo, Habek, Mario, Kalincik, Tomas

Prediction of relapse activity when switching to cladribine for multiple sclerosis

- Zhong, Michael, van der Walt, Anneke, Butler, Ernest, Prevost, Julie, Girard, Marc, Oh, Jiwon, Butzkueven, Helmut, Jokubaitis, Vilija, Monif, Mastura, Hodgkinson, Suzanne, Eichau, Sara, Kalincik, Tomas, Lechner-Scott, Jeannette, Buzzard, Katherine, Skibina, Olga, Van Pesch, Vincent